Proglumide

DRUG4 trials

Sponsors

Georgetown University

Conditions

Cirrhosis, LiverMetastatic Pancreatic CancerNonalcoholic SteatohepatitisPainPancreas FibrosisSafety Issues

Early Phase 1

Single-dose PK Assessment of Oral Proglumide in Those With Hepatic Impairment

CompletedNCT04814602

Georgetown UniversityCirrhosis, Liver

Start: 2021-03-30End: 2022-02-20Updated: 2022-03-15

Phase 1

Safety and Tolerability of Oral Proglumide for NASH

CompletedNCT04152473

Georgetown UniversityNonalcoholic Steatohepatitis

Start: 2019-12-13End: 2022-09-09Updated: 2022-10-13

Role of a CCK Receptor Antagonist Proglumide in Management of Chronic Pancreatitis

Active, not recruitingNCT05551858

Georgetown UniversityPain, Pancreas Fibrosis, Safety Issues

Start: 2022-11-17End: 2031-12-31Target: 32Updated: 2026-08-05

Phase 2

Proglumide and Chemotherapy for Metastatic Pancreatic Cancer

Active, not recruitingNCT05827055

Georgetown UniversityMetastatic Pancreatic Cancer

Start: 2024-01-31End: 2027-01-01Target: 30Updated: 2026-06-10

Related Papers

Proglumide, gemcitabine (GEM), and nab-paclitaxel (NAB-P) in patients (pts) with pancreatic ductal adenocarcinoma (PDAC): Results of the phase 1 PROGEM trial.

Journal of Clinical Oncology2026-05-27

Effects of Proglumide with Chemotherapy on the Pancreatic Tumor Microenvironment: Phase 1 PROGEM Trial

Pharmaceutics2026-03-19

Abstract B002: Effects of Proglumide with Chemotherapy on the Pancreatic Tumor Microenvironment: Phase 1 PROGEM Trial

Cancer Research2025-09-28